Who owns Kailera Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of KLRA from SEC Form 13F filings across 100 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 100 institutions disclosed 116.9M shares of Kailera Therapeutics, Inc. worth $2.57B — about 114.3% of shares outstanding; the largest disclosed holder is Bain Capital Investors LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
100
13F holders
$2.57B
value, 2026 filers
114.3%
of shares outstanding (116.9M sh)
100
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of KLRA's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Bain Capital Investors LLCNEW | 26.3M | $578.4M | 12.0% | 25.7% | new |
| 2 | Bain Capital Life Sciences Investors, LLCNEW | 22.6M | $497.5M | 29.6% | 22.1% | new |
| 3 | RTW INVESTMENTS, LPNEW | 10.8M | $237.4M | 2.0% | 10.5% | new |
| 4 | CANADA PENSION PLAN INVESTMENT BOARDNEW | 7.3M | $160.9M | 0.1% | 7.1% | new |
| 5 | Atlas Venture Life Science Advisors, LLCNEW | 5.2M | $113.9M | 12.9% | 5.1% | new |
| 6 | FMR LLCNEW | 4.0M | $87.5M | 0.0% | 3.9% | new |
| 7 | BlackRock, Inc.NEW | 3.9M | $86.5M | 0.0% | 3.8% | new |
| 8 | PRICE T ROWE ASSOCIATES INC /MD/NEW | 3.5M | $77.9M | 0.0% | 3.5% | new |
| 9 | CITADEL ADVISORS LLCNEW | 3.2M | $71.4M | 0.0% | 3.2% | new |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C.NEW | 3.2M | $70.7M | 0.1% | 3.1% | new |
| 11 | WELLINGTON MANAGEMENT GROUP LLPNEW | 2.9M | $64.3M | 0.0% | 2.9% | new |
| 12 | Royalty Pharma Sub-Manager, LLCNEW | 2.5M | $54.1M | 22.4% | 2.4% | new |
| 13 | Siren, L.L.C.NEW | 2.2M | $48.8M | 1.0% | 2.2% | new |
| 14 | VANGUARD CAPITAL MANAGEMENT LLCNEW | 1.7M | $37.3M | 0.0% | 1.7% | new |
| 15 | VANGUARD PORTFOLIO MANAGEMENT LLCNEW | 1.7M | $36.4M | 0.0% | 1.6% | new |
| 16 | GEODE CAPITAL MANAGEMENT, LLCNEW | 1.1M | $25.0M | 0.0% | 1.1% | new |
| 17 | FARALLON CAPITAL MANAGEMENT, L.L.C.NEW | 1.1M | $24.2M | 0.1% | 1.1% | new |
| 18 | Frazier Life Sciences Management, L.P.NEW | 1.1M | $24.2M | 0.5% | 1.1% | new |
| 19 | Trails Edge Capital Partners, LPNEW | 984,786 | $21.7M | 3.4% | 1% | new |
| 20 | UBS Group AGNEW | 972,683 | $21.4M | 0.0% | 1% | new |
| 21 | Jupiter Topco LLCNEW | 970,857 | $21.3M | 0.0% | 0.9% | new |
| 22 | STATE STREET CORPNEW | 868,160 | $19.1M | 0.0% | 0.8% | new |
| 23 | AMERIPRISE FINANCIAL INCNEW | 821,331 | $18.1M | 0.0% | 0.8% | new |
| 24 | Deep Track Capital, LPNEW | 700,000 | $15.4M | 0.2% | 0.7% | new |
| 25 | EVENTIDE ASSET MANAGEMENT, LLCNEW | 616,720 | $13.6M | 0.2% | 0.6% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.